Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial - Calkwood, J; Cree, B; Crayton, H (BMC Neurology, 2014)
et al.